País: Estats Units
Idioma: anglès
Font: NLM (National Library of Medicine)
PANTOPRAZOLE SODIUM (UNII: 6871619Q5X) (PANTOPRAZOLE - UNII:D8TST4O562)
WOCKHARDT LIMITED
PANTOPRAZOLE SODIUM
PANTOPRAZOLE SODIUM 20 mg
ORAL
PRESCRIPTION DRUG
Pantoprazole and its metabolites are excreted in the milk of rats. Pantoprazole excretion in human milk has been detected in a study of a single nursing mother after a single 40 mg oral dose. The clinical relevance of this finding is not known. Many drugs which are excreted in human milk have a potential for serious adverse reactions in nursing infants. Based on the potential for tumorigenicity shown for pantoprazole in rodent carcinogenicity studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the benefit of the drug to the mother. The effectiveness of pantoprazole sodium delayed-release tablets for treating symptomatic GERD in pediatric patients has not been established. Information describing use in pediatric patients with erosive esophagitis associated with GERD is approved for Wyeth Pharmaceuticals Inc.'s pantoprazole sodium delayed-release tablets. However, due to Wyeth Pharmaceuticals Inc.'s marketing exclusivity rights, this drug produc
How Supplied Pantoprazole sodium delayed-release tablets, USP are supplied as 20 mg yellow colored, biconvex oval shaped tablets plain on one side and imprinted with “W433” (brown ink) on other side. HDPE bottle of 30 tablets.............................NDC 64679-433-01 HDPE bottle of 90 tablets.............................NDC 64679-433-04 HDPE bottle of 1000 tablets.........................NDC 64679-433-02 Unit dose packages of 100 tablets…..........NDC 64679-433-03 HDPE bottle of 100 tablets...........................NDC 64679-433-05 Pantoprazole sodium delayed-release tablets, USP are supplied as 40 mg yellow colored, biconvex oval shaped tablets plain on one side and imprinted with “W434” (brown ink) on other side. HDPE bottle of 30 tablets............................NDC 64679-434-01 HDPE bottle of 90 tablets............................NDC 64679-434-04 HDPE bottle of 1000 tablets........................NDC 64679-434-02 Unit dose packages of 100 tablets.............NDC 64679-434-03 HDPE bottle of 100 tablets..........................NDC 64679-434-05 Storage Store at 20°-25°C (68°-77°F); [See USP Controlled Room Temperature].
Abbreviated New Drug Application
PANTOPRAZOLE SODIUM - PANTOPRAZOLE SODIUM TABLET, DELAYED RELEASE WOCKHARDT LIMITED ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS, USP SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS, USP. PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS, USP INITIAL U.S. APPROVAL: 2000 RECENT MAJOR CHANGES Indications and Usage, Pediatric (1) 11/2009 Dosage and Administration, Pediatric (2) 11/2009 Contraindications (4) 11/2009 Warnings and Precautions, Bone Fracture (5.4) 09/2010 INDICATIONS AND USAGE Pantoprazole sodium delayed-release tablet is a proton pump inhibitor indicated for the following: Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD) (1.1) Maintenance of Healing of Erosive Esophagitis (1.2) Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome (1.3) DOSAGE AND ADMINISTRATION INDICATION DOSE FREQUENCY See full prescribing information for administration instructions SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS ASSOCIATED WITH GERD ( 2.1 ) Adults 40 mg Once Daily for up to 8 wks MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS ( 2.1 ) Adults 40 mg Once Daily PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME ( 2.1 ) Adults 40 mg Twice Daily DOSAGE FORMS AND STRENGTHS Delayed-Release Tablets, 20 mg and 40 mg (3) CONTRAINDICATIONS Known hypersensitivity to any component of the formulation or to substituted benzimidazoles (4) WARNINGS AND PRECAUTIONS Symptomatic response does not preclude presence of gastric malignancy (5.1) Atrophic gastritis has been noted with long-term therapy (5.2) Bone Fracture Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine. (5) ADVERSE REACTIONS The most frequently occurring adverse reactions are as follows: For adult use (>2%) are headache, di Llegiu el document complet